Phase 2
N=71
Benfotiamine in Alzheimer's Disease: A Pilot Study
Alzheimer's Disease
Bottom Line
View on ClinicalTrials.gov: NCT02292238 ↗Enrolled (actual)
71
Serious AEs
8.6%
Results posted
Jun 2022
Primary outcome: Primary: Change From Baseline in ADAS-Cog Score — 1.39; 3.26 score on a scale — p=0.125
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Benfotiamine (Drug)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- Burke Medical Research Institute
- Primary completion
- Jul 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in ADAS-Cog Score |
1.39; 3.26 | 0.125 |
| SECONDARY Change From Baseline in Brain Glucose Utilization |
-0.02; -0.01 | 0.7529 |
| SECONDARY Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score |
-1.931; -3.16129 | 0.3687 |
| SECONDARY Change From Baseline in Neuropsychiatric Inventory (NPI) Score |
6.69; 9.23 | 0.4850 |
| SECONDARY Change From Baseline in Clinical Dementia Rating (CDR) Score |
0.05; 0.22 | 0.0337 sig |
| SECONDARY Change From Baseline in Buschke Selective Reminding Test (SRT) Score |
0.86; -1.12 | 0.315 |
Summary
General Investigational Plan
Study Objectives The goal of this proposal is to determine whether enhancing brain glucose utilization minimizes cognitive decline in patients with Amnestic Mild Cognitive Impairment (AMCI) or mild Alzheimer's disease (AD) dementia. We propose a proof of concept double-blind, placebo controlled pilot study to determine if increasing brain thiamine availability with the investigational new drug benfotiamine, will minimize the decline in glucose utilization and slow the cognitive decline associated with the progression AMCI/AD dementia.
Specifically, our objectives are two-fold:
* To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).
* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate.
We will also carry out the following secondary objectives:
* Assess if there are differences in secondary clinical outcome measures (NPI, ADCSADL, CDR, Buschke) between benfotiamine and placebo groups and whether specific cognitive domains (ie: activities of daily living, learning and memory verbal memory, behavioral, etc.) are driving these changes.
* Compare ADAS-COG change scores in the benfotiamine and placebo groups within and between strata that were defined by initial cognitive impairment, to attempt to identified the population that most benefits from benfotiamine.
* Compare changes in glucose utilization between the benfotiamine and placebo groups in secondary Regions of Interest (ROIs) including the hippocampus, prefrontal regions and entorhinal cortex.
* Compare changes in whole brain glucose utilization between the benfotiamine and placebo groups using statistical parametric mapping (SPM).
* Assess the correlation between changes in glucose utilization with changes in ADAS Cog.
* Determine if ApoE4 genotype alters the response to benfotiamine.
Eligibility Criteria
Inclusion Criteria
- 60 years of age or older
- Clinical diagnosis of AMCI by the Peterson criteria or probable AD dementia according to the National Institute of Neurological Disorders and stroke and the Alzheimer's Disease related Disorders Association (NINCDS/ADRDA)
- MMSE score > or equal to 21
- CDR score > or equal to 0.5 and 200 mg/ml).
- Patients with uncontrolled diabetes will be excluded because high glucose will alter the FDG-PET studies. The clinic that does PET (Columbia University Medical Center) excludes patients if glucose values exceed 200 mg/ml.
- A current diagnosis of active, uncontrolled seizure disorder
- A current diagnosis of probable or possible vascular dementia according to NINDS-AIREN
- An investigational drug during the previous 4 weeks
- A current diagnosis of severe unstable cardiovascular disease
- A current diagnosis of acute severe, or unstable asthmatic condition (e.g., severe chronic obstructive pulmonary disease (COPD),
- A current diagnosis of cardiac, renal or hepatic disease
- History of alcoholism, current or within past 5 years
- A disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, severe language difficulty)
- A1C less than or equal to 8
- Current diagnosis of cancer/active treatments
Data sourced from ClinicalTrials.gov (NCT02292238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.